Labcorp Holdings Inc. (LH)
| Market Cap | 18.17B |
| Revenue (ttm) | 13.01B |
| Net Income (ttm) | 746.00M |
| Shares Out | 83.67M |
| EPS (ttm) | 8.84 |
| PE Ratio | 24.56 |
| Forward PE | 13.53 |
| Dividend | $2.88 (1.33%) |
| Ex-Dividend Date | May 29, 2025 |
| Volume | 762,209 |
| Open | 217.75 |
| Previous Close | 220.57 |
| Day's Range | 217.06 - 219.97 |
| 52-Week Range | 191.97 - 258.59 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 266.44 (+22.75%) |
| Earnings Date | Apr 29, 2025 |
About LH
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target... [Read more]
Financial Performance
In 2024, Labcorp Holdings's revenue was $13.01 billion, an increase of 6.97% compared to the previous year's $12.16 billion. Earnings were $746.00 million, an increase of 78.47%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for LH stock is "Strong Buy." The 12-month stock price forecast is $266.44, which is an increase of 22.75% from the latest price.
News
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Count...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has...
Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Lab...
Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , Ap...
Labcorp to Announce First Quarter Financial Results on April 29, 2025
BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the firs...
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp ...
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a...
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive ad...
Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO C...
Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.
Labcorp forecasts 2025 revenue above estimates on diagnostic test demand
Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.
Labcorp Announces 2024 Fourth Quarter and Full Year Results
Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.7...
Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a firesid...
LABCORP DECLARES QUARTERLY DIVIDEND
BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025
BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth...
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
ST. LOUIS & HERCULES, Calif.--(BUSINESS WIRE)--Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories.
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labco...
Be Patient, Earn Dividends From Labcorp, The Leading Patient Clinical Lab Brand
For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth indic...
Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the develo...
Cinven secures Italian nod to sell minority stake in Synlab to Labcorp
Private equity firm Cinven secured a conditional approval from Italian authorities over its plan to sell a 15% stake in diagnostic service provider Synlab to laboratory operator Labcorp , a government...
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory serv...
Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience
CHICAGO & BURLINGTON, N.C.--(BUSINESS WIRE)--Collaboration leverages Praia Health's technology and Labcorp's comprehensive testing capabilities to streamline and personalize patient experience.
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and ...
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
Labcorp beats quarterly estimates on diagnostic test demand
Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.